HealthTab™ Expands to British Columbia in Select Shoppers Drug Mart® Locations
October 26 2021 - 7:00AM
AVRICORE HEALTH INC. (TSXV: AVCR) (the
"
Company" or “
AVCR”) announces
that it has expanded patient testing with the HealthTab™ platform
in select Shoppers Drug Mart® pharmacies in British Columbia,
bringing its diabetes screening program to Western Canada for the
first time.
“The launch in Shoppers Drug Mart pharmacies in Ontario has been
very successful and we are very happy to see the program lay the
groundwork for expansion,” said Hector Bremner, Avricore Health’s
CEO. “Having a real-time patient observation program reporting
seamlessly across 3000kms is very unique and we are very proud to
deliver this innovation.”
This expansion builds off the Master Agreement signed with
Shoppers Drug Mart Inc. to pilot the HealthTab™ platform in May of
this year which brings patients access to point-of-care blood
screening and health-data management for potential risks for
developing diabetes and cardiovascular conditions through the
HealthTab™-integrated Afinion 2™ analyzers by Abbott Rapid
Diagnostics.
"Patient feedback, along with that of our pharmacists, has been
very positive in Ontario with respect to HealthTab™ and we are
evaluating how more patients can benefit from this type of
service,” said Frank Hack, Director of Complex Care at Shoppers
Drug Mart. “In coming to British Columbia, we are hoping to learn
more about patient needs and serve them in the best way
possible.”
Shoppers Drug Mart® pharmacies in five cities have now received
their HealthTab™ systems and will begin offering screening tests to
patients with known conditions associated with pre-diabetes, or
already identified as diabetic, to provide diagnostic support and
pharmacist-led consultation services. They are located at:
- #5 Road & Cambie: 11800 Cambie Rd,
Richmond, BC
- Kensington Square: 6508 East Hastings St,
Burnaby, BC
- Thurlow & Davie: 1125 Davie St, Vancouver,
BC
- Cedar Hills: 12830 96th Avenue, Unit #6,
Surrey, BC
- Hillside Shopping Centre: 1644 Hillside Ave,
Victoria, BC
To find a location near you, please visit:
healthtab.com/locations
HealthTab™ Market Fast Facts
- Point-of-Care Testing Market to reach $50.6 Billion USD in 2025
(Source)
- Glucose monitoring (diabetes related) to make up the largest
growth with the sector. (Source)
- Nearly 13.6 Million Canadians expected to diabetic or
prediabetic by 2030, with many undiagnosed (Source)
- Over 1 in 3 Americans, approximately 88 million people, have
pre-diabetes (Source)
- Close to 160,000 Canadians 20 years and older are diagnosed
with heart disease each year, often it’s only after a heart attack
they are diagnosed. (Source)
- There are more that 10,000 pharmacies in Canada, 88,000
pharmacies in the US, nearly 12,000 in the UK.
About HealthTab™
HealthTab™ is a turnkey point-of-care testing solution that
combines best-in-class point-of-care technologies with a secure,
cloud-based platform for tackling pressing global health issues.
With just a few drops of blood from a finger prick, the system
generates lab-accurate results on the spot and data is reported in
real time. The test menu includes up to 23 key biomarkers for
screening and managing chronic diseases, such as diabetes and heart
disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab™ has also
recently added capabilities for bacterial and viral tests, such as
strep and COVID-19. The HealthTab™ network model is unlike anything
in pharmacy today. It gives knowledgeable and trusted pharmacists a
greater role in primary care delivery, while empowering patients to
take more control of their health. It also reduces costs and
waiting times and provides many potential revenue streams including
equipment leasing & consumables, direct access testing, disease
prevention & management programs, sponsored health programs,
decentralized clinical trials, real world data (RWD) sets, and
third-party app integration through API.
About Avricore Health Inc.
Avricore Health Inc. (TSXV: AVCR) is a pharmacy service
innovator focused on acquiring and developing early-stage
technologies aimed at moving pharmacy forward. Through its flagship
offering HealthTab™ (a wholly owned subsidiary), its mission is to
make actionable health information more accessible to everyone by
creating the world’s largest network of rapid testing devices in
community pharmacies.
Contact:
Avricore Health
Inc. Hector
Bremner, CEO 604-773-8943
info@avricorehealth.com www.avricorehealth.com
Cautionary Note Regarding Forward-Looking
Statements Information in this press release that involves
Avricore Health's expectations, plans, intentions or strategies
regarding the future are forward-looking statements that are not
facts and involve a number of risks and uncertainties. Avricore
Health generally uses words such as "outlook," "will," "could,"
"would," "might," "remains," "to be," "plans," "believes," "may,"
"expects," "intends," "anticipates," "estimate," "future,"
"positioned," "potential," "project," "remain," "scheduled," "set
to," "subject to," "upcoming," and similar expressions to help
identify forward-looking statements. In this press release,
forward-looking statements include statements regarding: the
completion of the placement and the expected timing thereof and the
Company's expected use of proceeds from the placement; the unique
features that the HealthTab™ platform offers to pharmacists and
patients. Forward-looking statements reflect the then-current
expectations, beliefs, assumptions, estimates and forecasts of
Avricore Health's management. The forward-looking statements in
this press release are based upon information available to Avricore
Health as of the date of this press release. Forward-looking
statements believed to be true when made may ultimately prove to be
incorrect. These statements are not guarantees of the future
performance of Avricore Health and are subject to a number of
risks, uncertainties and other factors, some of which are beyond
its control and may cause actual results to differ materially from
current expectations, including without limitation: failure to meet
regulatory requirements; changes in the market; potential downturns
in economic conditions; and other risk factors described in
Avricore's public filings. These forward-looking statements speak
only as of the date on which they are made, and the Company
undertakes no obligation to update them publicly to reflect new
information or the occurrence of future events or circumstances,
unless otherwise required to do so by law.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy
Avricore Health (TSXV:AVCR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avricore Health (TSXV:AVCR)
Historical Stock Chart
From Apr 2023 to Apr 2024